For current post-hoc study, all patients in the DACAB study were included in the analysis. Briefly, patients aged 18–80 years with indications for CABG using vein grafts were eligible for the trial. Major exclusion criteria included urgent revascularization or other concomitant cardiac surgery, a need for dual antiplatelet or vitamin K antagonist therapy after CABG, and serious bleeding risk. Detailed inclusion and exclusion criteria are listed in Table S1 .
Patients were randomly (in blocks of 3) assigned in a 1:1:1 ratio to receive ticagrelor (Brilinta, AstraZeneca) 90 mg twice daily plus aspirin 100 mg (Bayaspirin, Bayer) once daily, T + A regimen; ticagrelor 90 mg twice daily, T regimen; or aspirin 100 mg once daily, A regimen. Both on-pump and off-pump CABG was allowed in the trial and was selected according to the surgeons’ decisions. Only surgeons with the experience of more than 100 off-pump cases annually were invited to participate in the trial. The vein graft was openly harvested. The patients started their allocated regimen within 24 hours after the surgery, and the median duration of study treatment was 1 year.
Patients were randomly (in blocks of 3) assigned in a 1:1:1 ratio to receive ticagrelor (Brilinta, AstraZeneca) 90 mg twice daily plus aspirin 100 mg (Bayaspirin, Bayer) once daily, T + A regimen; ticagrelor 90 mg twice daily, T regimen; or aspirin 100 mg once daily, A regimen. Both on-pump and off-pump CABG was allowed in the trial and was selected according to the surgeons’ decisions. Only surgeons with the experience of more than 100 off-pump cases annually were invited to participate in the trial. The vein graft was openly harvested. The patients started their allocated regimen within 24 hours after the surgery, and the median duration of study treatment was 1 year.